Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golden Gate: Blinatumomab + low-intensity chemotherapy vs standard chemotherapy in older adults with newly diagnosed Ph-negative B-cell precursor ALL
jRCT2051210174Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Nov 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of blinatumomab in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Amgen. Started Nov 2021; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCT2051210174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210174.